This website is intended for an NZ health professional readership
@PharmacyToday is our weekly email newsletter, providing a snapshot of material appearing online in the previous seven days. It is usually delivered into your email in-box on a Wednesday.
Please note, you need a Pharmacy Today subscription to read the full articles. Have a nosy at our subscription options, here.
If you are interested in advertising in @PharmacyToday you can find more details here.
Not on our mailing list? No worries, use the form below to sign up to get a weekly overview of the top news stories in the pharmacy industry.
Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and drug-related morbidity and mortality. As such, gout needs to be addressed holistically as part of the psychosocial medical model
Patients can no longer be started on funded selegiline. Patients who were on selegiline prior to 1 August 2021 will need their prescriptions endorsed to receive subsidised supplies. An alternative MAO-B inhibitor, rasagiline, may be a suitable agent for new patients or those transitioning from selegiline.
This resource provides a timeline for the changes and information about transitioning patients from selegiline. Advice on prescribing rasagiline is also included.
